CROI 2023

The 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) was held in Seattle, US, from 19 to 22 February.

Interviews

CROI 2023: DoxyPEP for women

21 February 2023

At CROI 2023, Dr Jenell Stewart from the University of Washington spoke to NAM's Roger Pebody about doxyPEP for women.

CROI 2023: DoxyPEP and resistance

22 February 2023

At CROI 2023, Professor Annie Luetkemeyer from the University of California, San Francisco spoke with Liz Highleyman about doxyPEP and resistance.

CROI 2023: Mpox in people with low CD4 counts

22 February 2023

At CROI 2023, Professor Chloe Orkin from Queen Mary University of London spoke to NAM's Roger Pebody about mpox in people with low CD4 counts.

CROI 2023: Lenacapavir and two broadly neutralising antibodies for treatment

23 February 2023

 At CROI 2023, Professor Joseph Eron from University of North Carolina spoke to NAM's Roger Pebody about lenacapavir and two broadly neutralising antibodies for treatment.

CROI 2023: Integrase inhibitors and cardiovascular disease

22 February 2023

At CROI 2023, Dr Bernard Surial from the University of Bern spoke to NAM's Roger Pebody about integrase inhibitors and cardiovascular disease.

CROI 2023: Islatravir implant for PrEP

1 March 2023

At CROI 2023, Professor Alessandro Grattoni from Houston Methodist Hospital spoke to NAM's Roger Pebody about an islatravir implant for PrEP.

Conference bulletins

English

CROI 2023: Vaccine and doxycycline PEP both cut gonorrhoea rates, Tuesday 21 February 2023

CROI 2023: Mpox (monkeypox) can be very severe in people with uncontrolled HIV, Wednesday 22 February 2023

CROI 2023: Quarterly injections of PrEP may be effective for women, Thursday 23 February 2023

CROI 2023: Promising new PrEP method undergoes first safety study for anal sex, Wednesday 1 March 2023

French

CROI 2023: Le vaccin et la PEP à base de doxycycline contribuent tous les deux à une réduction des taux de gonorrhée, Mardi 21 février 2023

CROI 2023: Mpox (ex-variole du singe) peut être très grave chez les personnes séropositives immunodéprimées, Mercredi 22 février 2023

CROI 2023: Des injections trimestrielles de PrEP peuvent être efficaces chez les femmes, Jeudi 23 février 2023

CROI 2023: Une nouvelle forme de PrEP prometteuse fait l'objet de la première étude de tolérance pour les rapports sexuels avec pénétration anale, Mercredi 1er mars 2023

Spanish

CROI 2023: La vacunación y la PEP con doxiciclina contribuyen a reducir las tasas de gonorrea, Martes, 21 de febrero de 2023

CROI 2023: La mpox (viruela símica) puede ser muy grave en personas con el VIH sin controlar, Miércoles, 22 de febrero de 2023

CROI 2023: Las inyecciones trimestrales de PrEP pueden ser eficaces para las mujeres, Jueves, 23 de febrero de 2023

CROI 2023: Un prometedor nuevo método de PrEP supera el primer estudio de seguridad para el sexo anal, Miércoles, 1 de marzo de 2023

Portuguese

CROI 2023: PPE com vacina e doxiciclina reduzem as taxas de gonorreia, Terça-feira, 21 de fevereiro de 2023

CROI 2023: Mpox (monkeypox) pode ser muito grave em pessoas com VIH não controlado, Quarta-feira, 22 de fevereiro de 2023

CROI 2023: Injeções trimestrais de PrEP podem ser eficazes para mulheres, Quinta-feira, 23 de fevereiro de 2023

CROI 2023: Novo método promissor de PrEP passa no primeiro estudo de segurança para sexo anal, Quarta-feira, 1 de março de 2023

Italian

CROI 2023: Un vaccino e PEP con doxiciclina riducono entrambi il rischio di gonorrea, martedì 21 febbraio 2023

CROI 2023: L’mpox (vaiolo delle scimmie) può assumere forme molto gravi nelle persone con infezione da HIV incontrollata, mercoledì 22 febbraio 2023

CROI 2023: PrEP, per le donne potrebbe essere efficace anche una sola iniezione trimestrale, giovedì 23 febbraio 2023

CROI 2023: Nuovo promettente metodo di somministrazione della PrEP sottoposto al primo studio di sicurezza per il sesso anale, mercoledì 1 marzo 2023

Russian

КРОИ 2023: Вакцина и доксициклин, используемые в качестве постконтактной профилактики, сокращают уровень заболеваемости гонореей, Вторник, 21 февраля 2023 г.

КРОИ 2023: Обезьянья оспа (Mpox) может иметь очень тяжелое течение у лиц с неконтролируемой ВИЧ-инфекцией, Среда, 22 февраля 2023 г.

КРОИ 2023: Ежеквартальное введение инъекционного ДКП-препарата может быть эффективным у женщин, Четверг, 23 февраля 2023 г.

КРОИ 2023: Новый многообещающий метод доконтактной профилактики (ДКП) апробируется в первом исследование безопасности его применения при анальном сексе, Среда, 01 марта 2023 г.